Evaluation of the Safety of Slow IV Push Versus Slow IV Infusion Administration of 23.4% Sodium Chloride

被引:0
|
作者
Iskaros, Olivia [1 ,3 ]
Arnouk, Serena [2 ]
Papadopoulos, John [2 ]
Merchan, Cristian [2 ]
机构
[1] New York Univ Langone Hlth, New York, NY 10016 USA
[2] New York Univ Langone Hlth, New York, NY 10016 USA
[3] NYU Langone Hlth, Dept Pharm, 150 55th St, Brooklyn, NY 11220 USA
来源
NEUROHOSPITALIST | 2024年 / 14卷 / 02期
关键词
cerebral edema; 23.4% sodium chloride; IV push; slow IV infusion; hypotension; INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; HYPERTENSION; EFFICACY;
D O I
10.1177/19418744231216851
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose: Increased intracranial pressure due to cerebral edema is a medical emergency in which 23.4% sodium chloride (23.4% NaCl) may be a lifesaving intervention. Currently, safety data is limited on slow IV push (IVP) administration. The purpose of this study was to evaluate the safety of IVP administration of 23.4% NaCl and determine the number of infusion-related adverse events (IRAEs) compared to slow IV infusion (SIV) administration. Methods: We performed a retrospective review of patients who received a dose of 23.4% NaCl at the (removed institution) from January 2015 to June 2020 as either SIV over 30 minutes or IVP over 2-5 minutes. Results: In total, 81 patients, 55 in the IVP group and 26 in the SIV group, were included in the analysis. There was a significantly faster time from order entry to dose completion (IVP 25 [13,58] vs SIV 73 [55,113] minutes, P < .001). There was no difference in IRAEs between the groups (IVP 17 [31%] vs SIV 6 [23%], P = .466). Hypotension was most common (IVP 13 [24%] vs SIV 5 [19%], P = .656) followed by bradycardia (IVP 6 [11%] vs SIV 1 [4%], P = .291). There were no extravasations reported. Conclusions: Overall, among a cohort of patients with cerebral edema, we found no difference in the incidence of IRAEs between SIV and IVP administration of 23.4% NaCl, and found a faster time to complete administration fssor the latter. In emergent scenarios where time may impact neurologic function, 23.4% NaCl administered IVP may be an alternative to SIV administration.
引用
收藏
页码:122 / 128
页数:7
相关论文
共 35 条
  • [31] Comparative effects of rapid bolus administration of aqueous amiodarone versus 10-minute cordarone IV infusion on mean arterial blood pressure in conscious dogs.
    Somberg, JC
    Cvetanovic, I
    Ranade, V
    Molnar, J
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (02) : S359 - S359
  • [32] In-Vitro Safety Evaluation of Sodium Hypochlorite (NaOCI) as Part of Step 2 and Maintenance Therapy Protocols in Patients with Periodontitis Stages III-IV
    Kardaras, Giorgios
    Marcovici, Lasmina
    Rusu, Darian
    Dehelean, Cristina
    Coricovac, Dorina
    lorio-Siciliano, Vincenzo
    Sculean, Anton
    Stratul, Stefan-loan
    ORAL HEALTH & PREVENTIVE DENTISTRY, 2023, 21 (01) : 103 - 112
  • [33] Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients with Active Rheumatoid Arthritis: Results of a Six-Month, Multicenter, Randomized, Double- Blind, Controlled, Phase IV Trial
    Brezinschek, Hans-Peter
    JOURNAL FUR MINERALSTOFFWECHSEL, 2008, 15 (02): : 106 - 107
  • [34] Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo® hair growth factor formulation: A phase-IV, open-label, single-arm multi-ethnicity clinical trial
    Clinic, Aayna
    Asper, Annette
    Mittal, Apoorva
    Shome, Debraj
    Parbhoo, Deepa
    Thanzama, James
    Doshi, Komal
    Sachde, Neha
    Gaunkar, Ridhima
    Kapoor, Rinky
    Thakkar, Rukshmani
    Sion, Simal
    Shetty, Sushant
    Kumar, Vaibhav
    Parveen, Veena
    Singhal, Vivek
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (02) : 580 - 589
  • [35] Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
    Mateos, Maria-Victoria
    Nahi, Hareth
    Legiec, Wojciech
    Grosicki, Sebastian
    Vorobyev, Vladimir
    Spicka, Ivan
    Hungria, Vania T. M.
    Korenkova, Sibirina
    Bahlis, Nizar J.
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin
    Iida, Shinsuke
    Laubach, Jacob
    Ahmadi, Tahamtan
    Parasrampuria, Dolly A.
    Peng, Lixian
    Qi, Ming
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)